產(chǎn)品中心
PRODUCTS CENTER
多肽藥物中間體
在多肽藥物分子合成中,需要對(duì)中間體質(zhì)量進(jìn)行嚴(yán)格控制。我司依托自身分析分離技術(shù)平臺(tái)優(yōu)勢(shì),對(duì)各類中間體產(chǎn)品按照化藥API要求,深入開展質(zhì)量研究,并全方位支持注冊(cè)申報(bào)。
貨號(hào) | CAS號(hào) |
產(chǎn)品名稱 |
LK0046
|
1143516-05-5 | |
LK0069
|
843666-40-0 | |
LK0070
|
683239-16-9 |
................................................................................................................................................................................................................................................
貨號(hào) | CAS號(hào) |
產(chǎn)品名稱
|
LK0053
|
1662688-20-1 | |
LK0065 | 1169630-40-3 | |
LK0052 | 1118767-15-9 | |
LK0047
|
1118767-16-0 | |
LK0048 | 2061897-68-3 | |
LK0073 | 1446013-13-3 | |
LK0063 | 1890228-73-5 | |
LK0066 | 1446013-08-6 | |
LK0090 | 1446013-07-5 | Fmoc-His-Aib-OH |
LK0071 | 866044-63-5 | |
LK0078 | 1048377-78-1 |
................................................................................................................................................................................................................................................
貨號(hào) | CAS號(hào) |
產(chǎn)品名稱
|
LK0056
|
2915356-76-0 | |
LK0057 | 1118767-17-1 | |
LK0042 | 1188328-37-1 | |
LK0098 | 1188328-38-2 | C20-γ-Glu(AEEA-AEEA-OSu)-OH |
LK0061 | 2639221-78-4 | |
LK0062 | 2171139-20-9 | |
LK0064 | 2682040-93-1 | |
LK0067 | 186023-44-9 | |
LK0068 | 81672-17-5 |
................................................................................................................................................................................................................................................
貨號(hào) | CAS號(hào) |
產(chǎn)品名稱 |
LK0059 | 2612237-97-3 | |
LK0079 | 1931109-48-6 | |
LK0060 | / | |
LK0072 | 45120-30-7 | |
LK0075 | / | |
LK0076 | 1418291-58-3 | |
LK0088 | 1454254-70-6 | |
LK0077 | 1962160-86-6 | |
LK0080 | 1095952-22-9 | |
LK0081 | 878797-09-2 | |
LK0082 | 148515-78-0 | |
LK0083 | 1000164-43-1 | |
LK0084 | 2239-67-0 |
...............................................................................................................................................................................................................................................
ONLINE MESSAGE